PHILADELPHIA, Aug. 17, 2011 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company" or "Hemispherx") today announced its authorized agent GP Pharm Argentina has submitted to the ANMAT (Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica) regulatory agency responsible for the national administration of drugs, foods and medical technology for the approval of Alferon N Injection® for sales and distribution in Argentina. In June 2010, Hemispherx agreed to provide GP Pharm an option to market Alferon N Injection®, its FDA approved natural interferon, in Argentina and other Latin America countries as well. It is planned to be marketed under the brand name Naturaferon®. Alferon N Injection® is approved in the US for the treatment of refractory genital warts and a major scale-up of Alferon N Injection® manufacturing is underway at Hemispherx's New Brunswick, NJ facility.
